We count visits as totals without cookies, and never follow you from one day to the next. If you accept, we also use cookies to see how people use this site, so we can improve it. Privacy policy
Last close (USD)174.48+7.01 (+4.19%)as of 4 Nov 2026
Funds that hold it10One fund per scheme
Held through a master fund100 buy the stock themselves
Largest weight in a single fund5.08%Of that fund's NAV
Median weight3.29%Half the funds hold more than this
What does GILD do
Gilead Sciences, Inc.
Researches and makes HIV antivirals, hepatitis drugs and certain cancer drugs. Its main revenue comes from patented drugs sold to hospitals and pharmacies through large US distributors
BiktarvyVekluryTrodelvyYescartaVemlidy
Where the revenue comes from, and how much is left as profit (FY2025)
For every 100 dollars of sales: cost of sales 21 · operating expenses 45 · other income adds 0 · tax and other items 5 · leaving 29 as net profit
Which funds let you invest in GILD
Sorted by weight held, largest first
Investors in Thailand can buy GILD through 10 mutual funds open to retail investors. Most of them (10 funds) don't buy the stock themselves. Instead they invest in a master fund abroad, which in turn holds GILD.
The many funds holding less than 3% are usually index funds holding at market weight · Funds holding more than 8% have deliberately chosen a large position
How many funds each AMC holds it through
MFC
How Thai money reaches GILD
8 master funds
Master fund
Thai funds using this route
Master fund's GILD weight
BGF World Healthscience Fund
2
3.81%
several master funds
2
1.32%
BNP Paribas Funds Health Care Innovators
1
5.08%
Janus Henderson Horizon Biotechnology Fund
1
4.79%
AB International Health Care Portfolio
Data sourcesFunds that buy the stock themselves: top 5 holdings from the AMC's fact sheet as of 30 Sep 2026 · Funds that invest through a master fund: the master fund's portfolio from its issuer's fact sheet or prospectus · Each scheme counts as one fund · Share price: Market data · Financial statements: SEC EDGAR · Ratios: Market data · Revenue by business segment: SEC EDGAR · Weights are as of the report date, and funds can change their portfolios at any time · Investing involves risk. This is not investment advice.
Showing 10 of 10 funds you can buy · The full list is in the Expert view · Latest weights from portfolio reports, and funds can change their portfolios at any time · Past performance is not a guarantee of future performance
Valuation and key ratios
Gilead Sciences, Inc. · NASDAQ · Fiscal year ends in January
Market cap216.4B USD1.24 billion shares
P/E25.7xPrice ÷ FY2025 EPS 6.78
Forward P/E17.7xBased on forecast 12-month earnings
P/S7.0x
EV/EBITDA182.7x
Dividend yield1.86%3.25 USD per share a year
ROE40.5%Net profit ÷ shareholders' equity
Debt to equity (D/E)1.10xInterest-bearing debt
Beta0.37Against the S&P 500
Gross margin78.8%FY2025
Operating margin34.0%FY2025
Net margin28.9%FY2025
Price ratios use the latest close shown on this page · Forward P/E, P/S and EV/EBITDA from Market data · Beta from 5 years of monthly returns · Total dividends over the last 12 months
Company health made simple
From the FY2025 statements
Sales growth1.9%Slow growth
Yearly average over the last 4 years · Latest annual sales 29.4B USD
Profit from sales29%Highly profitable
For every 100 dollars of sales, about 29 dollars is left as net profit
Dividend1.86%Pays dividends
Per year, relative to the share price · Tech stocks tend to pay little because they reinvest their profits
1-year share price+41.9%Up
Now close to its 1-year high
A rise or fall in the share price doesn't move a fund by the same amount — a fund is affected only in proportion to how much it holds
Financial statements
Revenue grows 1.9% a year on average · EPS grows 8.3% a year on average
Annual · last 5 fiscal years
Revenue and net profit
FY202127.3B USD6.2B USD
FY202227.3B USD4.6B USD
FY202327.1B USD5.7B USD
FY202428.8B USD480.0M USD
FY202529.4B USD8.5B USD
Total revenue
Net profit
Quarterly · last 5 quarters
Revenue and net profit
Q2 FY20257.1B USD2.0B USD
Q3 FY20257.8B USD3.1B USD
Q4 FY20257.9B USD2.2B USD
Q1 FY20267.0B USD2.0B USD
Q2 FY20267.8B USD−10.5B USD
Annual income statement, balance sheet and cash flow
Item (USD)
FY2021
FY2022
FY2023
FY2024
FY2025
Total revenue
27.3B USD
27.3B USD
27.1B USD
28.8B USD
29.4B USD
Gross profit
20.7B USD
21.6B USD
20.6B USD
22.5B USD
23.2B USD
Operating profit
Free cash flow = operating cash flow − capital expenditure · A cell showing N/A is an item the statement doesn't report, not a zero · Source: SEC EDGAR
Technical analysis
Closed at 174.48 USD on 4 Nov 2026
Daily trendClear uptrendScore 0.50 on a scale of −1 to +1 · 1253 bars
RSI(14)
73.2
ADX(14)
32.1
Position in the price range
100%
Weekly trendClear uptrendScore 0.50 on a scale of −1 to +1 · 261 bars
RSI(14)
74.0
ADX(14)
24.3
Position in the price range
100%
Monthly trendClear uptrendScore 0.50 on a scale of −1 to +1 · 61 bars
RSI(14)
76.6
ADX(14)
44.8
Position in the price range
100%
Moving averages (daily)
Period
SMA
EMA
Price vs line
10 days
163.88
165.18
Above
20 days
158.28
160.27
Above
50 days
152.29
152.92
Above
100 days
142.53
146.54
Above
200 days
Indicators (daily)
Indicator
Value
Signal
RSI(14)
73.25
Down
MACD(12,26)
5.63
Up
ADX(14)
32.06
Neutral
ATR(14) % of price
1.56
Neutral
Support and resistance (weekly pivots)
s3146
s2151
s1
Trend score = average of the moving-average group and the indicator group ((up signals − down signals) ÷ number of signals) · RSI and ATR use Wilder's method · MACD uses the 12- and 26-period EMA · An ADX of 25 or above counts as a clear trend · Calculated from daily closing prices from Market data · Not investment advice
One fund counted per scheme · Funds investing through a master fund show the master fund's weight in GILD, not the look-through weight · Past performance is not a guarantee of future performance
1
3.61%
State Street Health Care Select Sector SPDR ETF
1
2.98%
several master funds (JHHBIU2 LX, ARKG US)
1
2.84%
several master funds (BlackRock Global Funds - World Healthscience)
SCBIHEALT(SSFE)SCB Healthcare Innovation
DAOL-GIHEALTH
MHEALTHGMFC Health Innovation Fund
LHHEALTH-ALH HEALTH INNOVATION FUND
TUSHEALTH-ATISCO US Healthcare Fund
ASP-IHEALTHAsset Plus Innovative Healthcare Fund
BCAP-XHEALTHBCAP NEXT GEN Health Fund
PWINPHILLIP WORLD INNOVATION FUND